Economic Evaluation of CDx to Optimize Oncology Treatment Costs
Companion diagnostics are not just clinical tools—they are also powerful economic levers in oncology care. By identifying patients most likely to benefit from high-cost targeted therapies, CDx can significantly improve cost-effectiveness and reduce healthcare waste. The Companion Diagnostics Market underscores the growing demand for health-economic analyses to justify reimbursement and adoption.
Targeted cancer drugs often come with price tags exceeding $100,000 per patient annually. Without CDx, these treatments may be prescribed to many patients who derive little or no benefit, driving up costs without improving outcomes. By narrowing the treatment population to biomarker-positive patients, CDx ensures better value for both payers and patients.
Health technology assessment (HTA) bodies increasingly require cost-effectiveness data before approving reimbursement for new drugs. CDx data can strengthen these cases by demonstrating improved quality-adjusted life years (QALYs) and reduced adverse event costs.
However, the economic benefits of CDx must be weighed against their own costs, which can be substantial, especially for advanced genomic profiling. Payers must also consider downstream savings from reduced hospitalizations, improved survival, and better quality of life.
As oncology care continues to shift toward precision medicine, integrating economic evaluation into CDx development will be critical for market access and long-term sustainability.